Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 6, 2000, Pages 771-775

  Kaneko, Akihiro ^a   Sasaki, Jiro ^a   Shimadzu, Mitsunobu ^b   Kanayama, Akiko ^b   Saika, Takeshi ^b   Kobayashi, Intetsu ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BACTERIUM MUTANT; GENE MUTATION; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS SANGUINIS;

STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS SANGUIS;

EID: 0034081337     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.6.771     Document Type: Article

References (17)

1. Chin, N. X. & Neu, H. C. (1984). Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 25, 319-26.
2. Bantar, C., Fernandez Canigia, L., Relloso, S., Lanza, A., Bianchini, H. & Smayevsky, J. (1996). Species belonging to the 'Streptococcus milleri' group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. Journal of Clinical Microbiology 34, 2020-2.
3. Piddock, L. J. (1994). New quinolones and gram-positive bacteria. Antimicrobial Agents and Chemotherapy 38, 163-9.
4. Sato, K., Hoshino, K., Tanaka, M., Hayakawa, I. & Osada, Y. (1992). Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrobial Agents and Chemotherapy 36, 1491-8.
5. Cantón, E., Pemán, J., Jimenez, M. T., Ramón, M. S. & Gobernado, M. (1992). In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrobial Agents and Chemotherapy 36, 558-65.
6. Kaneko, A., Tomita, F., Karakida, K. & Yamane, N. (1994). In-vitro antibacterial activity of SY5555 in dentistry and oral surgery. Chemotherapy (Tokyo) 42, 94-100.
7. Margerrison, E. E., Hopewell, R. & Fisher, L. M. (1992). Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. Journal of Bacteriology 174, 1596-603.
8. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
9. Jorgensen, J. H., Weigel, L. M., Ferraro, M. J., Swenson, J. M. & Tenover, F. C. (1999). Activities of newer fluoroquinolones against Streptococcus pneumonias clinical isolates including those with mutations in the gyrA, parC and parEloci. Antimicrobial Agents and Chemotherapy 43, 329-34.
10. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA.
11. Muñoz, R. & De La Campa, A. G. (1996). ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrobial Agents and Chemotherapy 40, 2252-7.
12. Sasaki, J., Karakida, K., Yamane, N., Ohta, Y., Busujima, Y. & Takakura, A. (1995). Antibacterial activity of balofloxacin against oral bacteria and the penetration into saliva and dental extraction wounds. Japanese Journal of Chemotherapy 43, 490-4.
13. Janoir, C., Zeller, V., Kitzis, M. D., Moreau, N. J. & Gutmann, L. (1996). High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrobial Agents and Chemotherapy 40, 2760-4.
14. Tankovic, J., Perichon, B., Duval, J. & Courvalin, P. (1996). Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrobial Agents and Chemotherapy 40, 2505-10.
15. Kitamura, A., Hoshino, K., Kimura, Y., Hayakawa, I. & Sato, K. (1995). Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1467-71.
16. Deguchi, T., Yasuda, M., Kawamura, T., Nakano, M., Ozeki, S., Kanematsu, E. et al. (1997). Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrobial Agents and Chemotherapy 41, 2544-6.
17. Pan, X. S. & Fisher, L. M. (1998). DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 42, 2810-16.